Interview with Edwin Harvey, Managing Director, Biogen Idec Argentina
Biogen Idec’s arrival in Argentina has been very recent. Could you explain to our readers why the time was right to take back your licences and to set up in…
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Argentina
Av. del Libertador 350 – 7th Floor
1638 Vicente Lopez – Buenos Aires
Argentina
Phone: +54 11 5550 8150
Fax: +54 11 4718 0805
www.biogenidec.com.ar
Biogen Idec’s arrival in Argentina has been very recent. Could you explain to our readers why the time was right to take back your licences and to set up in…
PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of…
The national coordinator of Plan Nacer and Plan Sumar – two social security programs to improve access to healthcare in Argentina – discusses universal coverage as a constitutional right, and the…
A senior director for Icon plc discusses Argentina’s strengths and weaknesses as a venue for clinical trials, the role the market plays in a global clinical trial strategy, and Icon’s…
Dr. Wanda Dobrzanski discusses Argentina’s potential and attractiveness as a clinical research environment and the biggest challenges facing local and global CROs in Argentina. How has political and popular…
Gador’s first general director from outside of the family discusses his mission, Gador’s key to success, and his method for successfully leading a company in Argentina’s unpredictable and volatile market.…
The founder of Eriochem discusses his firm’s ambitious technology based on a competitive IP strategy and its exciting research on a radically new oncology platform. Today, Eriochem is a vertically…
The general manager of IMS Health Argentina – South Cone weighs in on why his organization plays a crucial role in the pharma industry in Argentina. How does the Argentinean…
Dr. Valverde, a respected authority on pharmacovigilance from the University of Mamonides, discusses the emerging pharmaceutical trade relationship between China and Argentina in the context of the dynamic Argentinian industry.…
Laboratorios Elea’s General Manager tells the story of the laboratories outstanding growth over the previous five years, the his firms upcoming launch of the first Argentinian developed biosimilar product. To…
The founder of Bomi Group’s affiliate in Argentina discusses the accomplishments of his firm thus far, and the challenges they have faced while trying to enter the very consolidated Argentinian…
Aegerion’s representative in Argentina discusses her efforts to raise awareness of Homozygous Familial Hypercholesteremia (HoFH), the rare disease targeted by her company’s ultra-orphan drug, and the remaining challenges of diagnosing…
Daniel Varde, Deloitte’s top consultant for the healthcare and life sciences sector in Latin America, discusses the interaction of global, Latin American, and Argentinian healthcare trends, and strategic techniques for…
See our Cookie Privacy Policy Here